2-(2-氨基-6-苯基甲氧基嘌呤-9-基)乙酸乙酯 | 144084-39-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(2-氨基-6-苯基甲氧基嘌呤-9-基)乙酸乙酯
• 英文名称: ethyl 2-(2-amino-6-(benzyloxy)-9H-purin-9-yl)acetate
• 英文别名: ethyl (2-amino-6-(benzyloxy)purin-9-yl)acetate；2-amino-6-(benzyloxy)-9-[(ethoxycarbonyl)methyl]purine；2-amino-6-benzyloxy-9-carboethoxymethylpurine；9H-Purine-9-acetic acid, 2-amino-6-(phenylmethoxy)-, ethyl ester；ethyl 2-(2-amino-6-phenylmethoxypurin-9-yl)acetate
• CAS: 144084-39-9
• 化学式: C₁₆H₁₇N₅O₃
• 分子量: 327.343
• InChiKey: QFJMSHMOTFCDOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  105
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-氨基-6-苯基甲氧基嘌呤-9-基)乙酸乙酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以93%的产率得到ethyl (guanin-9-yl)acetate
  参考文献：
  名称：

  Synthesis of Peptide Nucleic Acid Monomers Containing the Four Natural Nucleobases: Thymine, Cytosine, Adenine, and Guanine and Their Oligomerization

  摘要：

  The preparation of mixed-sequence PNAs (PNAs containing the four natural nucleobases; thymine, cytosine, adenine, and guanine) is described. The PNA monomers containing thymine, Cbz-protected cytosine, or adenine or benzyl-protected guanine were prepared via convergent syntheses. Subsequent to introduction of the carboxymethyl linker at N-1 of the pyrimidines or N-9 of the purines and suitable protection of exocyclic groups, the nucleobase derivatives were coupled to the Boc-protected backbone esters 10a or 10b and finally hydrolyzed affording the monomers 12a-d. The exocyclic amino groups of cytosine and adenine were protected with a benzyloxycarbonyl group. The exocyclic amino group of guanine was left unprotected whereas O-6 was protected as the benzyl ether. Two mixed-sequence 10-mers, each with five purines incorporated, and a mixed-sequence 15-mer Containing seven purines were assembled essentially following standard solid phase peptide synthesis protocols.

  DOI：

  10.1021/jo00098a042
• 作为产物：
  描述：

  溴乙酸乙酯 、 O-6-苄基鸟嘌呤 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 以35%的产率得到2-(2-氨基-6-苯基甲氧基嘌呤-9-基)乙酸乙酯
  参考文献：
  名称：

  以嘌呤碱为P2-配体的新型HIV-1蛋白酶抑制剂的合成和生物学评估。

  摘要：

  将嘌呤碱基引入P2-配体可能会增强人类免疫缺陷病毒1（HIV-1）蛋白酶抑制的效力，因为羰基和NH基团促进了广泛的H键相互作用的形成。在这项工作中，合成和评估了33种化合物，其中含有N-2-（6-取代的9H-嘌呤-9-基）乙酰胺作为P2-配体以及4-甲氧基苯基磺酰胺的抑制剂16a，16f和16j作为P2'-配体，分别在体外对IC50的IC50浓度为43 nM，42 nM和68 nM表现出有效的抑制作用。

  DOI：

  10.1016/j.bmcl.2019.03.049

文献信息

• O.sup.6 -substituted guanine compositions and methods for depleting O.sup.6
  申请人：The United States of America as represented by the Department of Health

  公开号：US05691307A1

  公开（公告）日：1997-11-25

  Novel O.sup.6 -substituted guanine compounds and pharmaceutical compositions thereof are useful for effectively reducing O.sup.6 -alkylguanine-DNA alkyltransferase (AGT). The novel compounds are useful for treating tumors and when used with anti-neoplastic alkylating agents enhance the chemotherapeutic treatment of tumor cells in a host.

  新型O.sup.6-取代鸟嘌呤化合物及其药物组合物可有效降低O.sup.6-烷基鸟嘌呤-DNA烷基转移酶（AGT）的活性。这些新型化合物可用于治疗肿瘤，与抗肿瘤烷化剂一起使用时可增强宿主体内肿瘤细胞的化疗治疗效果。
• A Convenient Route to <i>N</i>-[2-(Fmoc)aminoethyl]glycine Esters and PNA Oligomerization Using a Bis-<i>N</i>-Boc Nucleobase Protecting Group Strategy
  作者：Filip Wojciechowski、Robert H. E. Hudson

  DOI：10.1021/jo800195j

  日期：2008.5.1

  A simple and practical synthesis of the benzyl, allyl, and 4-nitrobenzyl esters of N-[2-(Fmoc)aminoethyl]glycine is described starting from the known N-(2-aminoethyl)glycine. These esters are stored as stable hydrochloride salts and were used in the synthesis of peptide nucleic acid monomers possessing bis-N-Boc-protected nucleobase moieties on the exocyclic amino groups of ethyl cytosin-1-ylacetate

  描述了从已知的N-（2-氨基乙基）甘氨酸开始的N- [2-（Fmoc）氨基乙基]甘氨酸的苄基，烯丙基和4-硝基苄基酯的简单而实用的合成。这些酯以稳定的盐酸盐形式储存，用于合成在胞嘧啶-1-基乙酸乙酯，腺嘌呤-9-乙酸乙酯和乙酯的环外氨基上具有双-N -Boc保护的核碱基部分的肽核酸单体（O 6-苄基鸟嘌呤-9-基）乙酸盐。酯水解后，将相应的核碱基乙酸与N- [2-（Fmoc）氨基乙基]甘氨酸苄基酯或N- [2-（Fmoc）氨基乙基]甘氨酸烯丙基酯偶联，以保留N- [2-（Fmoc）氨基乙基]甘氨酸烯丙基酯。鸟嘌呤的O 6苄基醚保护基。Fmoc /双-N -Boc保护的单体已成功用于混合序列10-mer PNA低聚物的Fmoc介导的固相肽合成，并被证明是目前使用最广泛的Fmoc / Bhoc-保护的肽核酸单体。
• THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS
  申请人：BROWN Dennis M.

  公开号：US20160045502A1

  公开（公告）日：2016-02-18

  The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

  本发明描述了一种改善先前受到治疗性能不佳限制的治疗剂的治疗效果的方法和组合物，通过改善单药疗法的功效或减少副作用。这种方法和组合物特别适用于芥子碱基烷基化剂，例如尿嘧啶芥和其类似物、衍生物或前药，包括6-甲基尿嘧啶芥和6-乙基尿嘧啶芥。
• Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US11026914B2

  公开（公告）日：2021-06-08

  Methods and compositions suitable for the treatment of malignancies such as recurrent glioma and progressive secondary brain tumor are disclosed. These methods employ a hexitol derivative such as dianhydrogalactitol, a derivative or analog of dianhydrogalactitol, diacetyldianhydrogalactitol, or a derivative or analog of diacetyldianhydrogalactitol. The compositions can include such hexitol derivatives.

  本发明公开了适用于治疗复发性胶质瘤和进行性继发性脑瘤等恶性肿瘤的方法和组合物。这些方法采用己糖醇衍生物，如二氢半乳糖醇、二氢半乳糖醇的衍生物或类似物、二乙酰二氢半乳糖醇或二乙酰二氢半乳糖醇的衍生物或类似物。组合物可以包括此类己糖醇衍生物。
• Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase
  作者：Robert C. Moschel、Mark G. McDougall、M. Eileen Dolan、Linda Stine、Anthony E. Pegg

  DOI：10.1021/jm00101a028

  日期：1992.11

  A series of O6- and S6-substituted purine derivatives were tested for their ability to deplete the human DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) in cell-free extracts from HT29 colon tumor cells and intact HT29 cells. The order of potency was O6-(p-Y-benzyl)-guanine (Y = H, F, Cl, and CH3) > O6-benzyl-2'-deoxyguanosine > O6-(p-Y-benzyl)guanosine (Y = H, Cl, and CH3) greater-than-or-equal-to a series of 9-substituted O6-benzylguanine derivatives greater-than-or-equal-to O6-allylguanine > O6-benzylhypoxanthine > O6-methylguanine. A series of 7-substituted O6-benzylguanine derivatives, 2-amino-6-(p-Y-benzylthio)purine (Y = H, CH3),2-amino-6-[(p-nitrobenzyl)thiol-9-beta-D-ribofuranosylpurine, and 7-benzylguanine were inactive. It is concluded that for efficient AGT depletion, an allyl or benzyl group attached through exocyclic oxygen at position 6 of a 2-aminopurine derivative is required. Activity is preserved with a variety of substituent groups attached to position 9 while substitution at position 7 leads to a complete loss of activity.